Determining Mechanisms of Response to Polo-like Kinase 1 Inhibition in Non-Small Cell Lung Cancer

R Goonatilake - 2016 - digitalcommons.library.tmc.edu
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death
worldwide. The discovery of genetic alterations in some patients (~ 15%) has made it …

Tyrosine kinase signalling pathways in pancreatic cancer

CM Tactacan - 2015 - unsworks.unsw.edu.au
dc. description. abstract Pancreatic cancer (PC) still remains one of the most aggressive and
lethal of human cancers, with a lack of prognostic and predictive biomarkers and effective …

[引用][C] 医薬品のベネフィット/リスクを最適化するための用法用量設定に関する研究

作手千尋, ツクデチヒロ - 2018 - 熊本大学

[引用][C] Cancer Immunotherapy

R Ajina, D Aldeghaither, S Jablonski, LM Weiner - 2017 - Elsevier

[引用][C] Effects of gefitinib on quality of life and expression of inflammatory cytokines, T cell subsets and serum tumor markers in senile patients with NSCLC.

Y Zhu, J Lv, Y Zhou - Biomedical Research (0970-938X), 2017

[引用][C] Cancer genome sequence data combined with incidence statistics suggests large numbers of patients could benefit from off-label therapies.